Study of Lorlatinib in People With ALK-positive Non-small Cell Lung Cancer Whose Disease Progressed After Previous Treatment
Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI)
Category & Conditions: Cancer
Medicine: LORBRENA®(LORLATINIB)
ClinicalTrials.gov Identifier (NCT): NCT04362072
Protocol ID: B7461027
Open Plain Language Summary Result:
Click here